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Abstract
Objective: Adipose tissue has now emerged as a power-
ful endocrine organ via the production of adipokines. Vis-
fatin, a novel adipokine with diabetogenic and immuno-
modulatory properties has been implicated in the
pathophysiology of insulin resistance in patients with
obesity and Type-2 diabetes mellitus. The aim of this
study was to determine whether there are changes in the
maternal plasma concentration of visfatin with advancing
gestation and as a function of maternal weight.
Study design: In this cross-sectional study, maternal
plasma concentrations of visfatin were determined in
normal weight and overweight/obese pregnant women in
the following gestational age groups: 1) 11–14 weeks
(ns52); 2) 19–26 weeks (ns68); 3) 27–34 weeks (ns93);
and 4) )37 weeks (ns60). Visfatin concentrations were
determined by ELISA. Non parametric statistics were
used for analysis.
Results: 1) The median maternal plasma visfatin con-
centration was higher in pregnant women between
19–26 weeks of gestation than that of those between
11–14 weeks of gestation (P-0.01) and those between
27–34 weeks of gestation (P-0.01); 2) among normal
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weight pregnant women, the median plasma visfatin con-
centrations of women between 19–26 weeks of gestation
was higher than that of those between 11–14 weeks
(P-0.01) and those between 27–34 weeks (P-0.01);
and 3) among overweight/obese patients, the median
maternal visfatin concentration was similar between the
different gestational age groups.
Conclusion: The median maternal plasma concentration
of visfatin peaks between 19–26 and has a nadir
between 27–34 weeks of gestation. Normal and over-
weight/obese pregnant women differed in the pattern of
changes in circulating visfatin concentrations as a func-
tion of gestational age.
Keywords: Adipokines; obesity; overweight; pregnancy;
visfatin.
Introduction
Adipose tissue, originally considered to be a passive
depot for energy storage, has recently emerged as a
powerful endocrine organ via the production of adipo-
kines w61, 62, 154, 185–187x. The adipokine family
includes structurally and functionally diverse and highly
active peptides and proteins. Indeed, the adipokines
encompass cytokines we.g., tumor necrosis factor (TNF)-a
w76, 77, 96, 128, 190x and interleukin (IL)-6 w39, 59, 127,
151, 191, 192x, chemokines (e.g., monocyte chemo-
attractant protein-1) w122, 168x, mediators of vascular
hemostasis (e.g., plasminogen activator inhibitor-1) w5,
47, 174x, blood pressure (e.g., angiotensinogen) w84, 93x,
and angiogenesis (e.g., vascular endothelial growth fac-
tor) w37, 50x, as well as hormones regulating glucose
homeostasis (adiponectin w8, 15, 78, 85, 86, 115, 121,
130, 169x, resistin w12, 75, 97, 105, 178x, and leptin w51,
60, 63, 69, 110, 114, 203x). Much attention has been
focused on the endocrine actions of the adipokines, par-
ticularly to their suggested roles in regulating metabolic
processes. Adipokines have been implicated in the
pathophysiology of insulin resistance w25, 99, 112, 124,
158, 175, 179x, obesity w49, 100, 199x, hyperlipidemia
w52, 189x, and atherosclerosis w143–145x, thus providing
a putative mechanistic linkage between obesity and
abnormal metabolic conditions.
Recently, the important role of adipokines has been
corroborated in normal human gestation and common
complications of pregnancy: 1) increased circulating
maternal concentrations of leptin w10, 94, 99, 124x,
C-reactive protein (CRP) w124x, TNF-a w7, 10, 98, 99, 124,
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195x, resistin w35x and visfatin w102, 107x were reported
in patients with gestational diabetes mellitus (GDM). Con-
sistent with these findings, patients with GDM had lower
concentrations of adiponectin than normal pregnant
women w10, 40, 98, 156, 158, 184, 188, 197x; 2) over-
weight pregnant women have a lower plasma concentra-
tion of adiponectin w73, 134x and a higher concentration
of leptin w73x than non-obese pregnant women; and
3) preeclampsia is associated with increased concentra-
tions of leptin w4, 33, 73, 87, 113, 123, 136, 137, 147,
183x, visfatin w54x, and TNF-a w38, 101, 172x, as well as
decreased concentrations of resistin w34, 40x and altered
maternal circulating adiponectin w40, 71, 73, 90, 113,
131, 135, 155, 180x.
Visfatin, a newly discovered 52 kDa adipokine, had
already been identified more than a decade ago as a
growth factor for early B cell, termed pre-B cell colony-
enhancing factor (PBEF) w81, 119, 140, 166, 200x. The
re-discovery of visfatin as an adipose tissue derived hor-
mone has facilitated the investigation of its metabolic
effects. This adipokine is preferentially produced by vis-
ceral adipose tissue w79, 171, 182x, and exerts insulin-
mimicking effects w171, 198x through the activation of an
insulin receptor. In vitro exposure of adipocytes to glu-
cose results in increased secretion of visfatin w67x, and
visfatin deficient mice have an impaired glucose toler-
ance w159x. Studies in humans have demonstrated that
administration of glucose results in an increase in circu-
lating visfatin concentration w67x. In addition there is a
higher circulating concentration of this hormone in
patients with Type-2 diabetes mellitus (Type-2 DM) when
compared to non-diabetic subjects w36, 55, 111, 167x.
Only few studies have addressed the concentration of
visfatin in pregnant women w31, 53, 54, 65, 102, 107,
116, 117, 120x. Most of these reports are confined to
complications of pregnancy such as preeclampsia w53,
54x, fetal growth restriction w53, 116x and GDM w31, 65,
102, 107x. Only a single study reported maternal visfatin
concentrations along gestation w120x and there is no
information available regarding the comparison between
circulating visfatin in normal and overweight pregnant
women. Thus, the aims of this study were to determine
whether there are changes in maternal plasma concen-
tration of visfatin associated with advancing gestation
and as a function of maternal weight.
Materials and methods
A cross-sectional study was conducted by searching our clinical
database and bank of biological samples. Two-hundred and
seventy-three pregnant women with a normal singleton preg-
nancy were included in the study. The inclusion criteria were: 1)
no medical, obstetrical or surgical complications; 2) intact mem-
branes; 3) delivery of a term neonate ()37 weeks), and 4) birth
weight above the 10th percentile w6x. Women with multiple preg-
nancies, GDM and fetal congenital malformations were
excluded.
Maternal blood samples were obtained once from each preg-
nant woman at the following gestational ages: 1) 11–14 weeks
(ns52); 2) 19–26 weeks (ns68); 3) 27–34 weeks (ns93); and
4) )37 weeks (ns60). Blood was centrifuged at 1300=g for
10 min at 48C. The plasma obtained was stored at –808C until
the assay was performed.
The body mass index (BMI) in the first trimester was calcu-
lated according to the following formula: weight (kg)/height (m)2.
According to the definitions of the World Health Organization
(WHO) w1x, normal BMI was defined as 18.5–24.9 kg/m2 and
overweight/obese as BMI G25 kg/m2.
All women provided written informed consent prior to the col-
lection of maternal blood samples. The utilization of samples for
research purposes was approved by the institutional review
boards of Wayne State University, Sotero del Rio Hospital (Chile)
and the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD/ NIH/DHHS). Many of
these samples have been previously employed to study the biol-
ogy of inflammation, hemostasis, angiogenesis, and growth fac-
tors concentrations in normal pregnant women and those with
pregnancy complications.
Human visfatin C-terminal immunoassay
The concentrations of visfatin in maternal plasma were deter-
mined using specific and sensitive enzyme immunoassays pur-
chased from Phoenix Pharmaceuticals, Inc (Belmont, CA, USA).
Visfatin C-terminal assays were validated in our laboratory for
human plasma prior to the conduction of this study. Validation
included spike and recovery experiments, which produced par-
allel curves indicating that maternal plasma matrix constituents
did not interfere with antigen- antibody binding in this assay sys-
tem. Visfatin enzyme immunoassays are based on the principle
of competitive binding and were conducted according to the
manufacturer’s recommendations. Briefly, assay plates are pre-
coated with a secondary antibody and the non-specific binding
sites have been blocked. Standards and samples were incubat-
ed in the assay plates along with primary antiserum and bioti-
nylated peptide. The secondary antibody in the assay plates
bound to the Fc fragment of the primary antibody whose Fab
fragment competitively bound with both the biotinylated peptide
and peptide standard or targeted peptide in the samples. Fol-
lowing incubation, the assay plates were repeatedly washed to
remove unbound materials and incubated with a streptavidin-
horseradish peroxidase (SA-HRP) solution. Following incubation,
unbound enzyme conjugate was removed by repeated washing
and a substrate solution was added to the wells of the assay
plates and color developed in proportion to the amount of bio-
tinylated peptide-SA-HRP complex but inversely proportional to
the amount of peptide in the standard solutions or the samples.
Color development was stopped with the addition of an acid
solution and the intensity of color was read using a program-
mable spectrophotometer (SpectraMax M2, Molecular Devices,
Sunnyvale, CA, USA). Maternal plasma concentrations of visfatin
C were determined by interpolation from individual standard
curves composed of human visfatin peptide. The calculated
inter- and intra-assay coefficients of variation (CVs) for visfatin
C-terminal immunoassays in our laboratory were 5.3% and
2.4%, respectively. The sensitivity was calculated to be
0.04 ng/mL.
208 Mazaki-Tovi et al., Maternal visfatin concentration in normal pregnancy
Article in press - uncorrected proof
Table 1 Clinical and demographic characteristics of the study population.
11–14 19–26 27–34 G37 P*
weeks weeks weeks weeks
(ns52) (ns68) (ns93) (ns60)
Maternal age (years) 25.0 (22.0–31.0) 27.0 (22.0–33.0) 25.0 (21.0–31.0) 27.0 (22.0–30.0) 0.81
Parity 1 (0–2) 1 (0–2) 1 (0–1) 1 (0–2) 0.74
BMI (kg/m2) (23.2–27.0) 22.8 (21.0–25.2) 23.4 (21.6–26.3) 23.5 (22.0–25.6) 0.45
Gestational age at sampling (weeks) 13.0 (12.2–13.5) 20.7 (20.0–21.5) 31.7 (27.8–33.0) 39.5 (38.6–40.4) -0.01
Gestational age at delivery (weeks) 39.4 (38.7–40.4) 39.7 (38.7–40.4) 40.0 (39.0–40.4) 39.5 (38.6–40.1) 0.33
Birth weight (g) 3420 (3205–3660) 3380 (3120–3740) 3470 (3235–3702) 3415 (3157–3717) 0.67
Values are expressed as median and interquartile range (IQR); BMIsbody mass index.
*Kruskal-Wallis test.
Statistical analysis
The Shapiro-Wilk and Kolmogorov-Smirnov tests were used to
test for normal distribution of the data. Data were presented as
median and interquartile range (IQR) or median and range. Non-
parametric methods were used for parameters which were not
normally distributed such as maternal visfatin concentrations
and comparisons among groups were performed using the
Kruskal-Wallis test with post hoc test (Mann-Whitney U). For
those parameters which were normally distributed, parametric
tests were used for analysis and the comparisons among groups
were performed using one-way ANOVA with Bonferroni adjust-
ment for the calculated P-value in order to maintain the signifi-
cance level at 0.05.
Correlation between visfatin and gestational age at sampling,
maternal age, maternal BMI, birth weight and storage time was
conducted with the Spearman’s rank test. The statistical pack-
age employed was SPSS 14 (SPSS Inc., Chicago, IL, USA). A
P-value of -0.05 was considered statistically significant.
Results
The clinical and obstetrical characteristics of the study
groups are presented in Table 1. There were no signifi-
cant differences in maternal age, first trimester BMI, ges-
tational age at delivery and birth weight among the four
gestational age groups.
Maternal plasma concentrations of visfatin in
normal pregnancy
Visfatin was detected in the plasma of all subjects. Preg-
nant women between 19–26 weeks of gestation had a
higher median concentration of visfatin than those
between 11–14 weeks of gestation (median: 17.5 ng/mL
range: 5.6–31.0 vs. 15.0 ng/mL, 9.3–27.8, respectively;
P-0.01). Similarly, pregnant women between
19–26 weeks of gestation had a higher median concen-
tration of visfatin than those between 27–34 weeks of
gestation (median: 17.5 ng/mL range: 5.6–31.0 ng/mL vs.
14.8 ng/mL, 5.6–37.0, respectively; P-0.01) (Figure 1).
There was no significant difference in the median mater-
nal plasma visfatin concentration among the other
groups (Figure 1).
Comparison between maternal visfatin in normal
and overweight/obese women
Among normal weight pregnant women, the median
plasma visfatin concentrations between 19–26 weeks of
gestation were higher than that of those between
11–14 weeks (median: 18.1 ng/mL, range: 5.6–31.0 vs.
14.7 ng/mL, 9.4–27.8, respectively; P-0.01) and those
between 27–34 weeks (median: 18.1 ng/mL, range:
5.6–31.0 vs. 13.9 ng/mL, 5.6–36.4, respectively;
P-0.01) (Figure 2). In contrast, among overweight/obese
patients, the median maternal plasma visfatin concentra-
tion did not significantly differ among the various gest-
ational age groups.
The median maternal plasma visfatin concentration
was compared between normal and overweight/obese
patients regardless of gestational age group (Figure 2).
There was no correlation between the maternal plasma
visfatin concentration and maternal age, gestational age
at blood collection or birthweight irrespective of BMI
category or gestational age group.
Discussion
Principal findings of the study
1) Pregnant women between 19–26 weeks of gestation
had a significantly higher median plasma concentration
of visfatin than those between 11–14 weeks and
27–34 weeks of gestation; 2) among normal weight
women, the median plasma visfatin concentration at
19–26 weeks of gestation was higher than those
between 11–14 weeks and those between 27–34 weeks;
3) among overweight patients, the median maternal
visfatin concentration was similar between the
different gestational age groups.
Adipokines – a new culprit in insulin resistance
during pregnancy
Pregnancy is a unique physiologic state characterized by
profound and transitory insulin resistance w17, 21–23,
26–28, 42, 58, 64, 103, 104, 106, 109, 149, 157, 164,
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Figure 1 Comparison of median maternal plasma concentrations of visfatin between 11–14, 19–26, 27–34, and G37 weeks of
gestation. Pregnant women between 19–26 weeks of gestation had a higher median concentration of visfatin than women between
11–14 weeks of gestation (median: 17.5 ng/mL range: 5.6–31.0 vs. 15.0 ng/mL, 9.3–27.8, respectively; P-0.01). Similarly, pregnant
women between 19–26 weeks of gestation had a higher median concentration of visfatin than women between 27–34 weeks of
gestation (median: 17.5 ng/mL range: 5.6–31.0 vs. 14.8 ng/mL, 5.6–37.0, respectively; P-0.01). There was no difference in the
median maternal plasma visfatin concentration between the other groups.
Figure 2 Median maternal plasma visfatin concentrations during pregnancy in women of normal weight (BMI -25) and overweight/
obese (BMIG25). Among normal weight pregnant women, the median plasma visfatin concentration of women between 19–26weeks
of gestation was higher than those between 11–14 weeks (median: 18.1 ng/mL range: 5.6–31.0 vs. 14.7 ng/mL, 9.4–27.8, respectively;
P-0.01) and those between 27–34 weeks (median: 18.1 ng/mL range: 5.6–31.0 vs. 13.9 ng/mL, 5.6–36.4, respectively; P-0.01).
Among overweight/obese patients, the median maternal visfatin concentration was comparable between the different gestational age
groups.
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177x. This important metabolic alteration is thought to be
induced by placental hormones. Several lines of evi-
dence support this view: 1) in vitro, exposure of adipo-
cytes to progesterone, cortisol, prolactin, or human
placental lactogen, induced post binding defect in insulin
action w163x; 2) insulin resistance can be induced by
administration of human placental lactogen (HPL) w92,
165x, progesterone w14, 41, 91x, estrogen w41, 150x and
glucocorticosteroids w92x to non-pregnant subjects and
mice w13x; and 3) insulin resistance during pregnancy ris-
es in the third trimester w17, 21, 29, 164, 176, 193x with
the increase in the placental hormone secretion.
Previously, placental hormones were thought to be the
only culprits for insulin resistance in pregnancy. However,
with the recognition of the adipose tissue as a powerful
endocrine organ w45, 88, 89, 161x, its role in the patho-
physiology of insulin resistance via the production and
secretion of adipokines w61, 62, 154, 185–187x has been
established. The adipokine family includes highly active
molecules such as: IL-6 w191, 192x, TNF-a w77, 190x, lep-
tin w51, 60x, adiponectin w8, 15, 85, 121x, resistin w12, 75,
97, 105, 178x, and others w16, 105, 146, 160, 161x. Accu-
mulating evidence suggests that adipokines play a role
in the regulation of insulin resistance during human preg-
nancy: 1) maternal serum concentrations of leptin w120,
124, 126x, adiponectin w7, 25, 43, 112, 124, 158x, TNF-a
w7, 19, 99, 124–126x, resistin w71x and visfatin w120x are
correlated with insulin resistance indices such as homeo-
stasis model of assessment of insulin resistance (HOMA-
IR); 2) patients with gestational diabetes mellitus (GDM)
have increased concentrations of leptin w10, 94, 99, 124x,
C-reactive protein (CRP) w124x, TNF-a w7, 10, 98, 99, 124,
195x, resistin w35x and visfatin w102, 107x, and lower con-
centrations of adiponectin than normal pregnant women
w10, 40, 98, 156, 158, 184, 188, 197x; and 3) high con-
centrations of CRP w152, 196x and leptin w153x, as well
as low concentrations of adiponectin w194x in first and
early second trimester, are associated with increased risk
for GDM, suggesting a role for these adipokines in the
pathophysiology of this condition.
Visfatin is a novel adipokine with metabolic and
immunoregulatoric properties
Visfatin, a newly discovered 52 kDa adipokine, is pref-
erentially produced by visceral adipose tissue w79, 171,
182x. However, this protein is not tissue specific, and it
can be expressed in placenta, fetal membranes w95, 119,
132, 133, 139–142x and myometrium w48x, as well as in
bone marrow, liver, muscle w166x, heart, lung, kidney
w166x, macrophages w44x, and neutrophils w81, 166, 200x.
The specific physiologic role of visfatin has eluded elu-
cidation; nevertheless, increasing body of evidence sug-
gests that this hormone has immunoregulatory and
metabolic properties.
The role of visfatin in the regulation of the inflammatory
response has been highlighted in several reports: 1) vis-
fatin promotes the growth of B cell precursors w166x;
2) in vitro, visfatin up-regulates the production of the pro-
and anti-inflammatory cytokines (e.g., IL-6, TNF-a, IL-1b
and IL-10) by human monocytes, in a dose dependent
manner w129x; 3) the expression of visfatin is increased
following exposure to TNF-a (in monocytes w44x, macro-
phages w80x and neutrophils w81x), IL-6 (synovial w138x
and amniotic epithelial w139x cells), IL-8, as well as gran-
ulocyte/macrophage colony stimulating factor (in neutro-
phils w81x); 4) the expression of visfatin increased in cells
retrieved by bronchoalveolar lavage from patients with
acute lung injury w200x in neutrophils of septic patients,
w81x and in lung tissue of animals with acute lung injury
w201x; 5) patients with the -1001G allele in the visfatin
gene have increased risk of developing ARDS than wild-
type homozygotes, while the -1543T allele is associated
with decreased risk of developing ARDS in septic shock
patients w11x; and 6) patients with chronic inflammatory
disorders (e.g., inflammatory bowel disease, rheumatoid
arthritis) have an elevated serum visfatin concentration
w81, 200, 201x.
The evidence for the metabolic effect of this hormone
includes: 1) visfatin has insulin mimetic properties w171,
198x; 2) in vitro exposure of adipocytes to glucose results
in increased secretion of visfatin w67x; 3) serum concen-
tration of visfatin in humans correlates with the amount
of intra-visceral fat as determined by computerized
tomography scan w167x; 4) administration of glucose to
human subjects results in an increase in circulating vis-
fatin concentration w67x; 5) patients with Type-2 diabetes
mellitus or metabolic syndrome w56, 57x have higher cir-
culating visfatin concentrations than non-diabetic sub-
jects w36, 55, 111, 167x; and 6) visfatin serum
concentrations are higher in patients with GDM w102,
107x than in normal pregnant women.
Changes in plasma visfatin concentration during
normal pregnancy
Our findings that the median maternal plasma concen-
tration of visfatin peaks between 19–26 weeks and has
a nadir between 27–34 weeks of gestation only in normal
weight women, are novel. There are only a few reports
regarding circulating visfatin concentrations in pregnant
women w31, 53, 65, 102, 107, 116, 117, 120x. Indeed,
only a single study reported the results of comparison of
maternal visfatin concentrations between the three tri-
mesters of pregnancy w120x, and none included a com-
parison of circulating maternal visfatin concentrations
between normal and overweight pregnant women. Our
results are in agreement with the findings reported by
Mastorakos et al. w120x in which median concentration
of visfatin were higher in the second (24–26 weeks) and
third trimester (34–36 weeks) than those in the first tri-
mester (10–12 weeks) in a longitudinal study of 80 nor-
mal lean women. Our findings extend the latter report by
demonstrating that the increase in the median plasma
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visfatin concentration is confined to normal weight preg-
nant women. In addition, we included pregnant women
with a wide range of gestational ages; thus, we were able
to report a nadir in maternal visfatin concentrations dur-
ing the early third trimester.
Why are there fluctuations in circulating visfatin with
advancing gestation?
Given the diabetogenic effect of visfatin, it is tempting to
suggest that the median visfatin concentration increases
during pregnancy in association with insulin resistance
and the increase in maternal weight. Indeed, several
reports concerning non-pregnant subjects have argued
in favor of this association w18, 36, 55, 66–68, 111, 167x.
Our findings regarding the nadir in the median plasma
concentration of visfatin in the early third trimester, does
not support this hypothesis. Of note, recent reports have
challenged the association between visfatin and insulin
resistance w9, 20, 46, 70, 148x, BMI or obesity w46, 148x.
Hence, additional explanations must be thought in order
to explain our results.
Prima facie, our findings indicate that there is no asso-
ciation between weight gain during pregnancy and the
fluctuations in the median visfatin concentrations along
gestation. However, previous studies have indicted that
the highest maternal weight gain rate (expresses as the
increase in body weight per week) occurs during the
second trimester w3, 72, 74, 170x. Furthermore, the fetal
weight gain is lower during the second trimester than in
the third trimester; thus, second trimester maternal
weight gain reflects mainly maternal tissue growth. In
summary, the pattern of the alteration in maternal plasma
visfatin concentration with advancing gestation in normal
weight pregnant women may follow the changes in the
rate of maternal weight gain rather than weight gain per
se.
Pregnancy, maternal BMI and circulating visfatin
concentration – is increased BMI associated with
alteration in circulating visfatin?
The finding that normal and overweight/obese pregnant
women had a comparable median visfatin concentration
is novel. The association between circulating visfatin and
obesity, BMI and visceral fat depot is still shrouded with
uncertainty. Indeed, the lack of an association between
circulating visfatin and BMI w36, 46, 53, 55, 83, 102, 118,
173, 181, 202x, as well as a positive w18, 32, 108, 167x
and negative w31x association between the two have
been reported. Other investigators could not demon-
strate an association between visceral fat mass and plas-
ma visfatin concentrations w18x. Moreover, both higher
w18, 32, 56, 57, 66, 83, 167, 202x and lower w82, 148x
concentrations of visfatin in obese, than in normal sub-
jects, were reported. Although one can explain some of
the discrepancies by differences in the methods and the
characteristics of the various study groups, currently, it
is unclear whether or not circulating visfatin concentra-
tions are associated with body weight and adipose tis-
sue. In summary, the comparable median maternal
visfatin concentration between normal and overweight/
obese women reported herein, supports the recent stud-
ies challenging the suggested association between
visfatin and overweight and obesity.
We hypothesized that, in normal weight healthy preg-
nant women, the alteration in visfatin concentrations with
advancing gestation corresponds with the rate of mater-
nal weight gain. Interestingly, during pregnancy, over-
weight and obese patients gain less weight w2, 24, 30,
162x and at a slower rate w3x than normal weight women.
Thus, it is tempting to suggest that the different pattern
of maternal circulating visfatin concentrations with
advancing gestation in overweight than in normal weight
women reflects the decreased rate and the lower abso-
lute weight gain in overweight pregnant patients.
Currently, clinical data concerning maternal circulating
visfatin concentrations are scant. Indeed, this is the first
description of a nadir in maternal visfatin concentrations
in the early third trimester and a blunted change in mater-
nal circulating visfatin with advancing gestational age in
overweight pregnant women. A cause and effect rela-
tionship between BMI and maternal circulating visfatin
concentrations cannot be discerned from the data of the
present study; however, a plausible explanation for our
result can be the differences in weight gain rate in the
different trimesters and between normal and overweight
pregnant women, suggesting a role for visfatin in physio-
logic metabolic alterations of human pregnancy.
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